Resapp Health : Presentation at the ASX CEO Sessions

c2a72c21-b7c7-4a64-9256-e003dcc68a82.pdf

Digital healthcare for respiratory disease

Tony Keating

Chief Executive Officer and Managing Director [e-mail]

ASX The CEO Sessions 15 March 2016

ASX: RAP

Disclaimer

This presentation has been prepared by ResApp Health Limited ("ResApp"). The information contained in this presentation is a professional opinion only and is given in good faith. Certain information in this document has been derived from third parties and though ResApp has no reason to believe that it is not accurate, reliable or complete, it has not been independently audited or verified by ResApp. Any forward-looking statements included in this document involve subjective judgment and analysis and are subject to uncertainties, risks and contingencies, many of which are outside the control of, and may be unknown to, ResApp. In particular, they speak only as of the date of this document, they assume the success of ResApp's strategies, and they are subject to significant regulatory, business, competitive and economic uncertainties and risks. Actual future events may vary materially from the forward-looking statements and the assumptions on which the forward-looking statements are based. Recipients of this document (Recipients) are cautioned to not place undue reliance on such forward-looking statements. ResApp makes no representation or warranty as to the accuracy, reliability or completeness of information in this document and does not take responsibility for updating any information or correcting any error or omission which may become apparent after this document has been issued.

To the extent permitted by law, ResApp and its officers, employees, related bodies corporate and agents (Agents) disclaim all liability, direct, indirect or consequential (and whether or not arising out of the negligence, default or lack of care of ResApp and/or any of its Agents) for any loss or damage suffered by a Recipient or other persons arising out of, or in connection with, any use or reliance on this presentation or information.

This presentation is not an offer, invitation, solicitation or recommendation with respect to the subscription for, purchase or sale of any security, and neither this presentation nor anything in it shall form the basis for any contract or commitment whatsoever.

All amounts in Australian dollars unless stated otherwise.

Digital healthcare for respiratory disease

• Developing the world's first clinically-tested, regulatory-approved respiratory disease diagnostic test for smartphones

  • No additional hardware needed

  • Unique opportunity to integrate into telehealth providers' existing platforms

  • Apps to provide clinical-quality ('Gold Standard') diagnostic tests and chronic disease management tools directly to consumers and healthcare providers

• Huge global market, 700M+ doctor visits annually for respiratory disease1

• Strong clinical evidence from multiple pediatric clinical studies, adult study underway

• Successful Pre-Submission meeting held with the US FDA in Q1 2016

• Fully-funded to bring product to US market in late 2016

1. ResApp estimate based on OECD doctor visits per capita data and assuming 10% of visits are for respiratory disease (based on US data)

Company overview

Capital Structure (ASX:RAP)
Market Cap.	$151M
Share Price as of 14 March 2016	$0.26
Shares on Issue1	580M
Performance Shares2	93.75M
Options3	15.47M
Staff Incentive Options4	25M
Cash Balance as of 31 December 2015	$2.7M

1. Includes 121M escrowed shares

2. Issued on achieving $20M of annual revenue or on an acquisition

3. Exercise price of 2.6c, expire 31 December 2016

4. Issued to MD, 5M options at exercise price of 2.5c, 5M at 5c and 10M at 10c, 5 year expiry; Issued to Dr Abeyratne, 3M at 5c and 2M at 10c

Board of Directors

Dr Roger Aston Non-Executive Chairman (Chairman of Oncosil, former CEO of Mayne Pharma, Cambridge Antibody, cofounder of pSivida Corp)

Dr Tony Keating Managing Director and CEO (former Director, Commercial Engagement of UniQuest, engineering management roles with Exa Corporation)

Mr Brian Leedman Executive Director and VP

(Chair of AusBiotech-WA, co-founder of Imugene Ltd and Oncosil Medical Ltd, former VP, IR at pSivida Corp. and Group Marketing Manager at E&Y-WA) Mr Adam Sierakowski Non-Executive Director

Mr Chris Ntoumenopoulos Non-Executive Director

Substantial Shareholders

Freeman Road: 7.59% UniQuest Pty Ltd: 7.28%

Mr Brian Leedman: 5.28% Top 20 Shareholders: 43.7%